S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
Log in

NYSE:JNJJohnson & Johnson Stock Price, Forecast & News

$141.23
-2.03 (-1.42 %)
(As of 04/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$140.28
Now: $141.23
$145.42
50-Day Range
$111.14
MA: $135.11
$149.93
52-Week Range
$109.16
Now: $141.23
$154.50
Volume11.12 million shs
Average Volume10.67 million shs
Market Capitalization$372.33 billion
P/E Ratio20.83
Dividend Yield2.65%
Beta0.65
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.
Read More
Johnson & Johnson logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 5.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP47816010
Phone732-524-0400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.06 billion
Cash Flow$11.84 per share
Book Value$22.60 per share

Profitability

Net Income$15.12 billion

Miscellaneous

Employees132,200
Outstanding Shares2,636,352,000
Market Cap$372.33 billion
Next Earnings Date4/14/2020 (Confirmed)
OptionableOptionable

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.


Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

How has Johnson & Johnson's stock been impacted by COVID-19 (Coronavirus)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, JNJ shares have increased by 7.2% and is now trading at $141.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Johnson & Johnson?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Johnson & Johnson.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, April 14th 2020. View our earnings forecast for Johnson & Johnson.

How can I listen to Johnson & Johnson's earnings call?

Johnson & Johnson will be holding an earnings conference call on Tuesday, April 14th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings data on Wednesday, January, 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.87 by $0.01. The company had revenue of $20.75 billion for the quarter, compared to the consensus estimate of $20.83 billion. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The company's revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.97 EPS. View Johnson & Johnson's earnings history.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Thursday, January 2nd. Shareholders of record on Tuesday, February 25th will be paid a dividend of $0.95 per share on Tuesday, March 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Monday, February 24th. View Johnson & Johnson's dividend history.

How will Johnson & Johnson's stock buyback program work?

Johnson & Johnson announced that its board has approved a stock repurchase program on Monday, December 17th 2018, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.5% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's leadership believes its shares are undervalued.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY20 earnings guidance on Wednesday, January, 22nd. The company provided EPS guidance of $8.95-9.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.09. The company issued revenue guidance of +4.5-5.5% yr/yr to $85.8-86.2 billion, compared to the consensus revenue estimate of $85.52 billion.

What price target have analysts set for JNJ?

16 Wall Street analysts have issued 12-month price objectives for Johnson & Johnson's stock. Their forecasts range from $140.00 to $173.00. On average, they anticipate Johnson & Johnson's stock price to reach $157.07 in the next year. This suggests a possible upside of 11.2% from the stock's current price. View analysts' price targets for Johnson & Johnson.

Has Johnson & Johnson been receiving favorable news coverage?

Media stories about JNJ stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson earned a news impact score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutJohnson & Johnson.

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a increase in short interest in March. As of March 13th, there was short interest totaling 20,336,100 shares, an increase of 22.3% from the February 27th total of 16,630,000 shares. Based on an average daily trading volume, of 7,520,000 shares, the short-interest ratio is currently 2.7 days. Currently, 0.8% of the shares of the company are sold short. View Johnson & Johnson's Current Options Chain.

Who are some of Johnson & Johnson's key competitors?

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Walt Disney (DIS), Verizon Communications (VZ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), Procter & Gamble (PG), JPMorgan Chase & Co. (JPM), Exxon Mobil (XOM) and Home Depot (HD).

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 59)
  • Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
  • Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
  • Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
  • Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hexavest Inc. (0.04%), M&G Investment Management Ltd. (0.03%), State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Clifford Swan Investment Counsel LLC (0.01%) and Cacti Asset Management LLC (0.01%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Hubert Joly, Joaquin Duato, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed, Peter Fasolo, Ronald A Kapusta and William D Perez. View institutional ownership trends for Johnson & Johnson.

Which major investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., LGT Capital Partners LTD., Arlington Financial Advisors LLC, IFM Investors Pty Ltd, Ipswich Investment Management Co. Inc., Verity & Verity LLC, M&R Capital Management Inc., and Park National Corp OH. Company insiders that have sold Johnson & Johnson company stock in the last year include Kathryn E Wengel, and Michael E Sneed. View insider buying and selling activity for Johnson & Johnson.

Which major investors are buying Johnson & Johnson stock?

JNJ stock was purchased by a variety of institutional investors in the last quarter, including Hexavest Inc., Polaris Greystone Financial Group LLC, CHURCHILL MANAGEMENT Corp, IBM Retirement Fund, State of Alaska Department of Revenue, Cacti Asset Management LLC, American National Bank, and Tuttle Tactical Management. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince, Hubert Joly, Marillyn A Hewson, and William D Perez. View insider buying and selling activity for Johnson & Johnson.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $141.23.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $372.33 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis. Johnson & Johnson employs 132,200 workers across the globe. View additional information about Johnson & Johnson.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is http://www.jnj.com/.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel